Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Porcine Parainfluenza Virus Type 1 (“PPIV-1”), including novel genotypes thereof, all of which are useful in the preparation of immunogenic compositions and vaccines for treating and preventing disease in swine.
Type:
Grant
Filed:
August 30, 2019
Date of Patent:
May 25, 2021
Assignee:
Iowa State University Research Foundation, Inc.
Inventors:
Phillip Gauger, Jie Yeun Park, Karen M. Harmon, Jianqiang Zhang, Pablo Pineyro
Abstract: Disclosed herein are influenza vaccine compositions, related preparations and intermediates, formulations, production methods, immunization methods, and use thereof, for achieving improved immune-protection in human subjects. More specifically, non-egg-based influenza vaccines are described, which provide improved antigenic match.
Abstract: Provided is a method for detecting pathogenic microorganisms in a biological sample, which is a technique that can be used to perform high-sensitivity detection of pathogenic microorganisms, such as influenza virus, etc.
Abstract: The present invention provides a method for purifying an EV71 virus-like particle and a method for preparing a vaccine thereof. The virus-like particle is obtained by performing high density fermentation cultivation on recombinantly engineered bacteria; inducing expression of the EV71 virus-like particle protein expression using methanol; collecting the bacteria by centrifugation and performing high-pressure homogenization for disruption; performing precipitation on the supernatant with ammonium sulfate; and purifying by redissolution, ultrafiltration, ion exchange chromatography, molecular sieve chromatography, hydroxyapatite chromatography, etc.
Type:
Grant
Filed:
December 28, 2016
Date of Patent:
April 27, 2021
Assignee:
Beijing Minhai Biotechnology Co., Ltd.
Inventors:
Guoshun Li, Meirong Gu, Jiankai Liu, Lin Guo, Lei Chen, Gaimei Zhang, Yingzhi Xu, Jin Li, Haifeng Xiao
Abstract: The present invention relates to improved methods and assays for the detection of AAV neutralizing antibodies in sera. The present invention provides safe, sensitive and high throughput neutralization assays for antibody detection.
Type:
Grant
Filed:
December 2, 2016
Date of Patent:
April 20, 2021
Assignee:
VOYAGER THERAPEUTICS, INC.
Inventors:
Tatiana I. Novobrantseva, Dinah Wen-Yee Sah
Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based on the development of mutant CIV, having one or more mutations in segment 8, which induces a CIV-specific immune response in a subject.
Type:
Grant
Filed:
August 19, 2016
Date of Patent:
April 13, 2021
Assignees:
University of Rochester, Cornell University
Inventors:
Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
Type:
Grant
Filed:
August 18, 2020
Date of Patent:
April 13, 2021
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Robert Babb, Alina Baum, Gang Chen, Cindy Gerson, Johanna Hansen, Tammy Huang, Christos Kyratsous, Wen-Yi Lee, Marine Malbec, Andrew Murphy, William Olson, Neil Stahl, George D. Yancopoulos
Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen. A particular embodiment is a nucleic acid-based vaccine construct encoding a polypeptide comprising a full-length Zika virus prME antigen. A particular embodiment is a self-replicating RNA molecule comprising a construct encoding a polypeptide comprising a full-length Zika virus prME antigen.
Abstract: Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.
Type:
Grant
Filed:
May 2, 2019
Date of Patent:
March 30, 2021
Assignees:
TOKITAE LLC, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventors:
Ana Jaklenec, William Gates, Philip A. Welkhoff, Boris Nikolic, Lowell L. Wood, Jr., Robert S. Langer, Thanh Duc Nguyen, Stephany Yi Tzeng, James J. Norman, Kevin McHugh
Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.
Type:
Grant
Filed:
June 27, 2017
Date of Patent:
March 30, 2021
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
Type:
Grant
Filed:
September 15, 2020
Date of Patent:
March 23, 2021
Assignee:
Regeneren Pharmaceuticals, Inc.
Inventors:
Robert Babb, Alina Baum, Gang Chen, Cindy Gerson, Johanna Hansen, Tammy Huang, Christos Kyratsous, Wen-Yi Lee, Marine Malbec, Andrew Murphy, William Olson, Neil Stahl, George D. Yancopoulos
Abstract: An egg sealing unit for an automated biological sample collection system and method of use. The egg sealing unit seals the section of egg from which the shell has been removed. The egg sealing unit includes a sampler, an applicator and an imaging adaptor providing an optical conduit between the surface of an egg and the CAM. The applicator is configured to deliver exogenous material to the CAM, the sampler is configured to collect samples from the CAM and the imaging adaptor allows the CAM to be monitored.
Type:
Grant
Filed:
August 15, 2019
Date of Patent:
March 23, 2021
Assignee:
INNOVO MIMETICS LIMTED
Inventors:
Robert Goldstein, Jonathan Goldstein, Avner Yeffet, Julia Rifman, Renana Hajbi, Leah Blum
Abstract: Disclosed is a universal influenza vaccine composition and corresponding methods comprising at least one attenuated live-attenuated influenza vaccine. The vaccine composition can exhibit a cross-protective effect against a wide range of influenza viruses and can ensure a strong protection efficacy, a wide range of protection, and safety. In addition, a vaccination method of heterologous live vaccines of the present invention induces various immunological effects so that cross-immunogenicity and cross-protective ability are remarkably increased, and thus is expected to be usefully utilized as a universal influenza prevention method. A person who has a basal immunity through infection with an influenza virus or vaccination with an influenza vaccine can be regarded as being in a state where primary vaccination has already been performed, single vaccination with a live vaccine induces an enhanced cross-immune response, and thus it is possible to expect a wide range of protective effects against various viruses.
Type:
Grant
Filed:
February 1, 2019
Date of Patent:
March 23, 2021
Assignee:
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Inventors:
Baik Lin Seong, Yo Han Jang, Young Ho Byun
Abstract: Described are improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the described improved processes relate to improved processes for producing viral DNA template. Also described are improved processes for chromatography purification of nucleic acid-containing compositions, in which the nucleic acid is quantified in chromatography fractions using a rapid detection method of the one or more nucleic acid sequences of the nucleic acid-containing composition, such as detection by real time RT-qPCR. In addition, improved processes for production and purification of oncolytic poliovirus, such as PVS-RIPO, are described. Compositions generated using these methods are also provided.
Type:
Grant
Filed:
June 10, 2016
Date of Patent:
March 23, 2021
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Trevor Lane Broadt, Samir Hussein Shaban, Yueqing Xie, Jianwei Sean Zhu, George Mitra
Abstract: Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.
Type:
Grant
Filed:
April 9, 2019
Date of Patent:
March 2, 2021
Assignee:
California Institute of Technology
Inventors:
Benjamin E. Deverman, Paul H. Patterson, Viviana Gradinaru
Abstract: The present invention relates to a method for the immunological diagnosis of a sample from a patient with a potential infection with an arbovirus, wherein a) a sample is brought into contact with a plurality of antigens that, separated from each other, are applied to a solid phase, wherein at least the following antigens are used: aa) the “non-structural protein 1” of a first arbovirus or an immunologically reactive part thereof having at least 8 amino acids, bb) an “envelope protein” of a first arbovirus or an immunologically reactive part thereof having at least 8 amino acids, cc) an “envelope protein” of a second arbovirus or an immunologically reactive part thereof having at least 8 amino acids, dd) the “non-structural protein 1” of a third arbovirus or an immunologically reactive part thereof having at least 8 amino acids and ee) an “envelope protein” of a third arbovirus or an immunologically reactive part thereof having at least 8 amino acids, b) the solid phase is washed to separate non-specific b
Type:
Grant
Filed:
October 17, 2017
Date of Patent:
February 16, 2021
Assignee:
Mikrogen GmbH
Inventors:
Erwin Soutschek, Oliver Boecher, Christina Noelting
Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.
Abstract: Compounds, compositions, and methods are provided for covalently linking an antibody or an antibody fragment to a cargo molecule, such as a therapeutic or a diagnostic agent, using a combination of enzymatic glycan remodeling and click chemistry. The method allows a cargo molecule to be selectively and efficiently attached post-translationally to an antibody or an antibody fragment. Also provided are antibody drug conjugates, methods of making, and uses thereof.
Type:
Grant
Filed:
April 8, 2015
Date of Patent:
February 2, 2021
Assignee:
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Abstract: Provided is a dimer antibody including two structural domains independently each represented by the following amino acid sequence, in an N- to C-direction, N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C wherein the antibody is capable of binding to a norovirus; FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; any one of the following requirements (i)-(iii) is satisfied.